Q1 2025 Earnings Estimate for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Issued By Zacks Research

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Research analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for shares of Alnylam Pharmaceuticals in a report issued on Wednesday, June 26th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn ($1.06) per share for the quarter, down from their previous forecast of ($0.95). The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($3.92) per share. Zacks Research also issued estimates for Alnylam Pharmaceuticals’ Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.80) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.58) EPS, Q1 2026 earnings at $0.31 EPS and FY2026 earnings at $2.58 EPS.

Several other research analysts also recently weighed in on the stock. SVB Leerink upped their target price on shares of Alnylam Pharmaceuticals from $138.00 to $159.00 and gave the stock a “market perform” rating in a report on Tuesday, June 25th. Citigroup upped their target price on shares of Alnylam Pharmaceuticals from $227.00 to $291.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $283.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, June 21st. Morgan Stanley upped their target price on shares of Alnylam Pharmaceuticals from $164.00 to $250.00 and gave the stock an “equal weight” rating in a report on Tuesday, June 25th. Finally, Wells Fargo & Company increased their price objective on shares of Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the company an “equal weight” rating in a report on Tuesday, June 25th. Eight research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $246.41.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $243.32 on Monday. The company has a market capitalization of $30.78 billion, a P/E ratio of -90.79 and a beta of 0.37. The company has a fifty day moving average of $161.82 and a 200 day moving average of $164.96. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $252.87.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to the consensus estimate of $428.01 million. The company’s quarterly revenue was up 54.8% on a year-over-year basis. During the same period in the prior year, the company posted ($1.40) EPS.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC increased its holdings in Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares during the period. Altitude Crest Partners Inc. purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $30,000. Quent Capital LLC increased its holdings in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 123 shares during the period. Anchor Investment Management LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at approximately $38,000. Finally, Robeco Institutional Asset Management B.V. increased its holdings in Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 12,513 shares during the period. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the sale, the director now directly owns 136 shares of the company’s stock, valued at approximately $30,013.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director David E. I. Pyott sold 32,450 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the sale, the director now directly owns 136 shares of the company’s stock, valued at approximately $30,013.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $276,726.02. Following the transaction, the executive vice president now directly owns 14,181 shares in the company, valued at $3,275,669.19. The disclosure for this sale can be found here. Insiders have sold 67,357 shares of company stock valued at $13,436,711 in the last ninety days. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.